Tocilizumab to prevent side effects from ramantamig in multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma and have measurable disease
- You have received at least one prior cancer treatment for myeloma
- Your myeloma has relapsed (came back after initial response) or is refractory (didn't respond or stopped responding to treatment)
- You are generally able to care for yourself, with a performance status score of 0–2
- Your blood work and organ function meet study requirements
- You are not currently receiving other cancer treatments and have not had major surgery within the past 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This trial tests whether adding the drug ramantamig to standard treatments (daratumumab, bortezomib, lenalidomide, and dexamethasone) works better for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. It compares three treatment groups to find the safest and most effective option.
This study tests whether a drug called sirolimus, given before certain immunotherapy treatments (teclistamab or talquetamab), helps these treatments work better against multiple myeloma. These immunotherapies teach your immune cells to attack myeloma cells.
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.